Zimmer Biomet (ZBH) Q3 2025 10-Q Quarterly Report
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR Zimmer Biomet (ZBH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Zimmer Biomet Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $2.001B Q3 2025, up 9.7% vs $1.824B Q3 2024; Nine months $5.988B, up 5.9% vs $5.655B 2024
- • Operating profit margin Q3 17.6% vs 15.3% YoY; Nine months 15.8% vs 15.9% YoY (slight decrease)
- • Best segment: Americas Q3 operating margin 51.6% vs 53.3% YoY, worst: EMEA 29.2% vs 32.9% YoY
- • Cash $1.293B as of Sept 30, 2025; operating cash flow $1.180B nine months, financing cash inflow $1.223B due to senior notes issuance
- • Management expects full year 2025 revenue growth 6.7%-7.7%, earnings decline due to acquisition costs, inflation, tariffs, higher interest, tax rate increase
Risk Factors
- • No new or changed risk factors since 2024 Form 10-K disclosed in this 10-Q
- • Continued exposure to product liability and regulatory compliance risks from medical device industry regulations
- • Ongoing market risk from global healthcare budget constraints and competitive orthopedic device market
- • Operational risk from supply chain disruptions impacting product availability and manufacturing timelines
- • Financial risk includes potential impact from foreign currency fluctuation on international sales and earnings
Zimmer Biomet Q3 2025 Quarterly FinancialsXBRL
Revenue
$2.0B
▲ +9.7% YoY▼ -3.7% QoQ
Net Income
$231M
▼ -7.3% YoY▲ +51.0% QoQ
Net Margin
11.5%
▼ -212bp YoY▲ +418bp QoQ
Source: XBRL data from Zimmer Biomet Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Zimmer Biomet Quarterly Reports
Get deeper insights on Zimmer Biomet
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.